Health Care & Life Sciences » Biotechnology | Cantabio Pharmaceuticals Inc.

Cantabio Pharmaceuticals Inc. | Income Statement

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
SG&A Expense
86.90
25.30
840.90
1,069.30
1,348.80
EBIT
86.90
25.30
840.90
1,069.30
1,348.80
Unusual Expense
-
-
107.90
3.00
43.00
Non Operating Income/Expense
-
-
18.30
-
-
Interest Expense
-
-
-
39.90
620.00
Pretax Income
86.90
25.30
751.30
1,112.10
2,011.80
Consolidated Net Income
86.90
25.30
751.30
1,112.10
2,011.80
Net Income
86.90
25.30
751.30
1,112.10
2,011.80
Net Income After Extraordinaries
86.90
25.30
751.30
1,112.10
2,011.80
Net Income Available to Common
86.90
25.30
751.30
1,112.10
2,011.80
EPS (Basic)
0.00
0.00
0.04
0.04
0.07
Basic Shares Outstanding
22,819.20
24,250.00
18,216.50
26,805.30
30,943.80
EPS (Diluted)
0.00
0.00
0.04
0.04
0.07
Diluted Shares Outstanding
22,819.20
24,250.00
18,216.50
26,805.30
30,943.80
EBITDA
86.90
25.30
840.90
1,069.30
1,348.80

About Cantabio Pharmaceuticals

View Profile
Address
1250 Oakmead Parkway
Sunnyvale California 94085
United States
Employees -
Website http://www.cantabio.com
Updated 09/14/2018
Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company which engages in the commercialization of novel therapies and the intellectual property generated from the research and development activities for Parkinson's, Alzheimer's diseases, and any other related diseases. It focuses on identification and development of small molecule pharmacological chaperones targeting proteins that misfold and aggregated in vivo vivo levels of proteins which display loss of function during disease conditions. The company was founded by Gergely Toth on November 2015 and is headquartered in Sunnyvale, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.